Entity Address, City or Town Entity Address, City or Town Office and laboratory space. Office And Laboratory Space [Member] Office and Laboratory Space Combined licenses Combined Licenses [Member] Combined Licenses [Member] Increase decrease in operating lease liability current. Increase Decrease In Operating Lease Liability Current Operating lease liability, current portion Net income (loss) Net income (loss) attributable to common shareholders - basic Net Income (Loss) Available to Common Stockholders, Basic, Total Net Income (Loss) Available to Common Stockholders, Basic Fair Value Disclosures [Abstract] Net income (loss) per share attributable to common shareholders: Earnings Per Share [Abstract] Fair Value, Inputs, Level 1 [Member] Quoted Prices in Active Markets for identical Assets (Level 1) Stock Issued During Period, Value, New Issues Issuance of common shares Aggregate offering price Net Cash Provided by (Used in) Financing Activities [Abstract] Cash Flows From Financing Activities: Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Expected dividend yield Interest receivable Accrued Investment Income Receivable Amendment Flag Amendment Flag Property and equipment purchases incurred but not yet paid Capital Expenditures Incurred but Not yet Paid Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Number of shares authorized to be issued Subsequent Event Type [Domain] Subsequent Event Type Deferred Income Tax Assets, Net, Total Deferred Income Tax Assets, Net Deferred tax assets Operating Lease, Right-of-Use Asset Operating lease right-of-use assets Collaboration term expiration period. Collaboration Term Expiration Period Collaboration term expiration period Document Quarterly Report Document Quarterly Report Accrued expenses and other liabilities current Accrued Expenses And Other Liabilities Current Total accrued expenses and other current liabilities Increase decrease in operating lease liability net. Increase Decrease In Operating Lease Liability Net Operating lease liability, net of current portion Milestones payments. Milestones Payments Milestones payments Preferred Stock, No Par Value Preferred stock par value Cash and Cash Equivalents [Domain] Cash and Cash Equivalents Statement [Table] Statement [Table] Operating Lease, Liability, Noncurrent Operating lease liability, net of current portion Collaboration And License Agreement [Member] Collaboration and License Agreement Collaboration and license agreement. Operating cash flows used for operating leases Operating minimum lease payments Operating Lease, Payments Issuance of common shares under the 2020 Employee Share Purchase Plan, Shares Stock Issued During Period, Shares, Employee Stock Purchase Plans Preferred Stock, Shares Outstanding, Ending Balance Preferred Stock, Shares Outstanding, Beginning Balance Preferred Stock, Shares Outstanding Preferred stock shares outstanding Shares of common stock reserved for future issuance Common Stock, Capital Shares Reserved for Future Issuance Estimated Shares Issuable Under the ESPP Estimated Shares Issuable Under the ESPP [Member] Estimated shares issuable under the ESPP. Common Stock, No Par Value Common stock par value US Treasury Notes Securities [Member] U.S. Treasury Notes Increase (Decrease) in Deferred Revenue Deferred revenue Increase (Decrease) in Income Taxes Income taxes Product and Service [Axis] Product and Service Roche Hoffmann La Roche Inc and F Hoffmann La Roche Ltd [Member] Hoffmann La Roche Inc and F Hoffmann La Roche Ltd Fair value, assets, transfers between all levels. Fair Value Assets Transfers Between All Levels Fair value, assets, transfers between levels Employee-related Liabilities, Current, Total Employee-related Liabilities, Current Accrued compensation and benefits Lessee, Operating Leases [Text Block] Leases Share-Based Payment Arrangement, Option [Member] Stock Options Weighted-average remaining lease term (in years) Operating Lease, Weighted Average Remaining Lease Term Liabilities and Equity TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY Organization and nature of business. Organization And Nature Of Business [Line Items] Organization and Nature of Business [Line Items] Plan Name [Domain] Plan Name Other Liabilities, Current, Total Other Liabilities, Current Other Office Building [Member] Office Space Weighted Average Number of Shares Outstanding, Diluted [Abstract] Denominator: Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Income Statement [Abstract] Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Organization and Nature of Business Deferred Revenue, Total Deferred Revenue Deferred revenue Sale of Stock [Domain] Sale of Stock Liabilities, Current Total current liabilities Stock Issued During Period, Value, Employee Stock Purchase Plan Issuance of common shares under the 2020 Employee Share Purchase Plan Interest Income, Securities, US Treasury Fair Value, Recurring [Member] Fair Value Measurements, Recurring Money market funds included in cash and cash equivalents Money Market Funds Included in Cash and Cash Equivalents [Member] Money Market Funds Included in Cash and Cash Equivalents [Member] Short-Term Lease, Cost Short-term lease costs Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Operating Lease, Weighted Average Discount Rate, Percent Weighted-average discount rate Entity Small Business Entity Small Business Commercial milestones. Commercial Milestones [Member] Commercial Milestones Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Investments [Domain] Investments Two thousand twenty equity incentive plan. Two Thousand Twenty Equity Incentive Plan [Member] 2020 Equity Incentive Plan Assets, Current Total current assets Interest receivable for US treasury notes Interest Receivable For U S Treasury Notes Interest receivable for US treasury notes. Weighted Average Number of Shares Outstanding, Basic, Total Weighted Average Number of Shares Outstanding, Basic Weighted-average common shares outstanding-basic City Area Code City Area Code Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Number of shares, Cancelled or forfeited Share-Based Payment Arrangement [Abstract] Liabilities TOTAL LIABILITIES Document Period End Date Document Period End Date Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Fair value of stock options Debt Securities, Available-for-Sale, Amortized Cost Amortized Cost Contract with Customer, Liability, Noncurrent Deferred revenue, net of current portion Statistical Measurement [Axis] Statistical Measurement Assets TOTAL ASSETS COVID19 pandemic. C O V I D19 Pandemic Policy [Text Block] COVID-19 Pandemic Diluted Net income (loss) per share attributable to common shareholders-diluted Earnings Per Share, Diluted, Total Earnings Per Share, Diluted Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Numerator: Computation of Diluted Net Income (Loss) Per Share in Attributable to Common Shareholders Indicate to Anti Diluted Effect Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Deferred financing costs in accruals and other current liabilities Deferred financing costs in accruals and other current liabilities. Deferred Financing Costs In Accruals And Other Current Liabilities Entity Address, Postal Zip Code Entity Address, Postal Zip Code Unrealized Gain (Loss) On Derivatives Unrealized Gain (Loss) on Derivatives Document Fiscal Period Focus Document Fiscal Period Focus Cost of services Cost of Goods and Services Sold Cost of Goods and Services Sold, Total Preferred shares, no par value per share; unlimited shares authorized as of September 30, 2022 and December 31, 2021, respectively; 0 shares issued and outstanding as of September 30, 2022, and December 31, 2021, respectively Preferred Stock, Value, Issued, Ending Balance Preferred Stock, Value, Issued, Beginning Balance Preferred Stock, Value, Issued, Total Preferred Stock, Value, Issued APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Share-based compensation expense Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Statement of Financial Position [Abstract] Entity File Number Entity File Number Increase (Decrease) in Prepaid Expense Prepaid expenses Statement of Cash Flows [Abstract] Geographical [Domain] Geographical Statistical Measurement [Domain] Statistical Measurement Statement of Stockholders' Equity [Abstract] Sale of Stock [Axis] Sale of Stock Income Taxes Receivable Income tax receivable Legal Entity [Axis] Legal Entity Lease, Cost [Table Text Block] Summary of Lease Costs Increase decrease in accrued expenses and other current liabilities. Increase Decrease In Accrued Expenses And Other Current Liabilities Accrued expenses and other current liabilities Purchase price of shares as percentage of fair market value of common stock on date of purchase. Purchase Price Of Shares As Percentage Of Fair Market Value Of Common Stock On Date Of Purchase Purchase price of shares as percentage of fair market value of common stock on date of purchase Subsequent Events [Abstract] Fair Value Disclosures [Text Block] Fair Value Measurements Dilutive impact of outstanding stock options and shares issuable under the ESPP Incremental Common Shares Attributable to Dilutive Effect of stock options and shares issuable under the ESPP Dilutive impact of outstanding stock options and shares issuable under the ESPP. Proceeds from Stock Options Exercised Proceeds from exercise of stock options Aggregate proceeds from exercise of options Transfer of clinical trial materials Transfer of Clinical Trial Materials [Member] Transfer of Clinical Trial Materials [Member] Antidilutive Securities [Axis] Antidilutive Securities Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block] Schedule of Transaction Price Performance Obligations Deferred Revenue, Revenue Recognized Deferred revenue recognized Contract with Customer, Liability, Current Deferred revenue, current portion Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Unrealized Gains Unrealized gains Lessee, Lease, Description [Line Items] Lessee Lease Description [Line Items] Subsequent Events [Text Block] Subsequent Events Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Weighted-average common shares outstanding - diluted Weighted Average Number of Shares Outstanding, Diluted, Total Weighted Average Number of Shares Outstanding, Diluted Weighted-average common shares outstanding-diluted Follow-on Offering Follow On Offering [Member] Follow-on offering. Cash received from purchases under ESPP Proceeds from (Repurchase of) Equity Proceeds from (Repurchase of) Equity, Total General and Administrative Expense [Member] General and Administrative QUEBEC Montreal, Quebec Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Unrecognized share-based compensation expense related to unvested stock options Current Fiscal Year End Date Current Fiscal Year End Date Investment Type [Axis] Investment Type Schedule of accrued expenses and other current liabilities. Schedule Of Accrued Expenses And Other Current Liabilities Table [Text Block] Schedule of Accrued Expenses and Other Current Liabilities Option to license druggable target lesions. Option To License Druggable Target Lesions [Member] Options to License Druggable Target Lesions Depreciation, Total Depreciation Depreciation expense Financial Instruments [Domain] Revenue from collaboration agreements. Revenue From Collaboration Agreements Collaboration agreements Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Cash and cash equivalents and restricted cash at end of period Cash and cash equivalents and restricted cash at beginning of period Other Assets, Noncurrent, Total Other Assets, Noncurrent Other assets Entity Address, Address Line One Entity Address, Address Line One Deferred Revenue, Noncurrent, Total Deferred Revenue, Noncurrent Deferred revenue, noncurrent Cash, Cash Equivalents, and Marketable Securities [Text Block] Cash and Cash Equivalents and Marketable Securities Common stock capital shares initially reserved for future issuance. Common Stock Capital Shares Initially Reserved For Future Issuance Shares of common stock initially reserved for future issuance Supplemental Cash Flow Information [Abstract] Supplemental Disclosure Of Cash Flow Information: Proceeds from issuance of common stock under the 2020 Employee Share Purchase Plan Proceeds from Issuance of Common Stock under Two Thousand Twenty Employee Share Purchase Plan Proceeds from issuance of common stock under two thousand twenty employee share purchase plan. Repare Therapeutics Incorporation option plan. Repare Therapeutics Incorporation Option Plan [Member] Option Plan Income Tax Expense (Benefit), Total Income Tax Expense (Benefit) Income tax recovery (expense) Preferred Stock, Shares Issued, Total Preferred Stock, Shares Issued Preferred stock shares issued Payments to Acquire Property, Plant, and Equipment, Total Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Research service payments entitled to be received Revenue, Remaining Performance Obligation, Amount Milestone payments entitled to be received Preferred Stock, Shares Authorized, Unlimited [Fixed List] Preferred stock shares authorized U.S. Treasury bills US Treasury Bill Securities [Member] Stock Issued During Period, Shares, New Issues Issuance of common shares, Shares Shares issued Recently Issued Accounting Pronouncements Not Yet Adopted Recently Issued Accounting Pronouncements Policy [Text Block] Recently issued accounting pronouncements. Assets, Fair Value Disclosure [Abstract] Assets Increase (Decrease) in Other Receivables Other receivables Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV Revenue Recognized Contract with Customer, Liability, Revenue Recognized Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Weighted average exercise price, Cancelled or forfeited Income (loss) from operations Operating Income (Loss) Lessee, Operating Lease, Option to Extend Operating lease, option to extend, description Additional Paid in Capital, Common Stock, Ending Balance Additional Paid in Capital, Common Stock, Beginning Balance Additional Paid in Capital, Common Stock Additional paid-in capital Options to purchase common shares. Options To Purchase Common Shares [Member] Options to Purchase Common Shares Collaborative Arrangement and Arrangement Other than Collaborative [Table] Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Accrued Professional Fees, Current Accrued professional services Accrued Liabilities and Other Liabilities, Total Accrued Liabilities and Other Liabilities Accrued expenses and other current liabilities Entity Filer Category Entity Filer Category Payments to Acquire Marketable Securities, Total Payments to Acquire Marketable Securities Purchase of marketable securities Proceeds from Sale and Maturity of Marketable Securities, Total Proceeds from Sale and Maturity of Marketable Securities Proceeds from maturities of marketable securities Annual increase in number of shares available for issuance maximum number of common stock issued. Annual Increase In Number Of Shares Available For Issuance Maximum Number Of Common Stock Issued Annual increases in number of shares available for issuance maximum number of common stock issued Total other comprehensive loss Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Operating Expenses Total operating expenses Entity Current Reporting Status Entity Current Reporting Status New lease agreement. New Lease Agreement [Member] New Lease Agreement Asset Class [Domain] Asset Class Research development and regulatory milestones. Research Development And Regulatory Milestones [Member] Research, Development and Regulatory Milestones Stockholders' Equity Attributable to Parent Balance Balance Total shareholders’ equity Investment Income, Net, Total Investment Income, Net Interest income Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Asset Class [Axis] Asset Class Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] Summary of Cash and Cash Equivalents and Marketable Securities Entity Tax Identification Number Entity Tax Identification Number Income Statement Location [Axis] Income Statement Location Common shares, no par value per share; unlimited shares authorized as of September 30, 2022 and December 31, 2021; 41,961,510 and 41,850,162 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively Common Stock, Value, Issued, Ending Balance Common Stock, Value, Issued, Beginning Balance Common Stock, Value, Issued, Total Common Stock, Value, Issued Retained Earnings (Accumulated Deficit), Ending Balance Retained Earnings (Accumulated Deficit), Beginning Balance Retained Earnings (Accumulated Deficit), Total Retained Earnings (Accumulated Deficit) Accumulated deficit Unrealized loss on available-for-sale marketable securities OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total Equity Components [Axis] Equity Components Research and development tax credits receivable. Research And Development Tax Credits Receivable Research and development tax credits receivable Prepaid expenses and other current assets Prepaid Expense, Current, Total Prepaid Expense, Current Prepaid expenses Leases [Abstract] Non-refundable payment received Contract with Customer, Liability, Total Contract with Customer, Liability Transaction price Entity Emerging Growth Company Entity Emerging Growth Company Operating Expenses [Abstract] Operating expenses: Collaboration revenue receivable Receivables, Long-Term Contracts or Programs Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Expected terms (in years) Debt Securities, Available-for-Sale [Table] Debt Securities Available For Sale [Table] Document Transition Report Document Transition Report Assets, Fair Value Disclosure Total financial assets Assets, Fair Value Disclosure, Total Total other income, net Nonoperating Income (Expense) Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Accrued Expenses and Other Current Liabilities Net income loss and comprehensive income loss. Net Income Loss And Comprehensive Income Loss Net loss and comprehensive loss Net loss and comprehensive loss Collaborative Arrangement Disclosure [Text Block] Collaboration and License Agreement Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Weighted average exercise price, Exercised Options, weighted-average exercise price Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Effect of exchange rate fluctuations on cash held Accumulated other comprehensive loss Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Increase (Decrease) in Deferred Income Taxes Deferred tax Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Other comprehensive loss Other Comprehensive Income (Loss), Net of Tax Other Comprehensive Income (Loss), Net of Tax, Total Net income (loss) Net income (loss) Net Income (Loss) Attributable to Parent Operating Lease, Liability, Current Operating lease liability, current portion Collaboration revenue receivable Amoun t of collaboration revenue receivable Additional Paid-in Capital [Member] Additional Paid-in Capital Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative Number of operating leases. Number Of Operating Leases Number of operating leases Entity Registrant Name Entity Registrant Name Cash and cash equivalents at end of period Cash and cash equivalents at beginning of period Cash and Cash Equivalents, at Carrying Value, Total Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Net Income (Loss) per Share Earnings Per Share [Text Block] Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of Fair Value of Stock Options Determined on Grant Date Using Black Scholes Option-Pricing Model Lessee, Lease, Description [Table] Lessee Lease Description [Table] Share-based Payment Arrangement, Noncash Expense, Total Share-Based Payment Arrangement, Noncash Expense Share-based compensation expense Property, Plant and Equipment, Net, Ending Balance Property, Plant and Equipment, Net, Beginning Balance Property, Plant and Equipment, Net, Total Property, Plant and Equipment, Net Property and equipment, net Award Type [Domain] Award Type Statement [Line Items] Statement [Line Items] Title of 12(b) Security Title of 12(b) Security Increase (Decrease) in Accounts Payable, Total Increase (Decrease) in Accounts Payable Accounts payable Common Stock Member Common Stock [Member] Common Shares Net Cash Provided by (Used in) Operating Activities [Abstract] Cash Flows From Operating Activities: Equity Component [Domain] Equity Component Income (loss) before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Entity Address, State or Province Entity Address, State or Province Geographical [Axis] Geographical Net Decrease In Cash And Cash Equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Document Type Document Type Proceeds from Collaborators Initial nonrefundable upfront fee received Accrued research and development expense current. Accrued Research And Development Expense Current Accrued research and development expense Entity Shell Company Entity Shell Company Share based compensation arrangement by share based payment award number of shares ceased granting. Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Ceased Granting Number of shares ceased granting Share-Based Payment Arrangement, Expense Total share-based compensation expense Share-based compensation expense Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value, Recurring and Nonrecurring [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] increase decrease in research and development tax credits receivable. Increase Decrease In Research And Development Tax Credits Receivable Research and development tax credits receivable Security Exchange Name Security Exchange Name Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Organization and nature of business. Organization And Nature Of Business [Table] Organization And Nature Of Business [Table] Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Net cash provided by (used in) operating activities Net Cash Provided by (Used in) Operating Activities Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Unrecognized share-based compensation expense related to unvested stock options, weighted average period Accrued Income Taxes, Current Income tax payable Additional paid in capital share-based payment arrangement exercised options credited to common shares. Additional Paid In Capital Share Based Payment Arrangement Exercised Options Credited To Common Shares Decrease in additional paid-in capital as exercised options credited to common shares Operating Lease, Cost Operating lease costs Consolidation, Policy [Policy Text Block] Principles of Consolidation Share-Based Payment Arrangement, Option, Activity [Table Text Block] Schedule of Outstanding Stock Options Recently Adopted Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Common Stock, Shares, Outstanding, Ending Balance Common Stock, Shares, Outstanding, Beginning Balance Common Stock, Shares, Outstanding Common stock shares outstanding Net (accretion)/amortization of marketable securities Accretion (Amortization) of Discounts and Premiums, Investments Over-Allotment Option [Member] Exercise of Underwriters Option Entity Address, Country Entity Address, Country Fair Value, Inputs, Level 2 [Member] Significant Other Observable Inputs (Level 2) Deferred Revenue, Current, Total Deferred Revenue, Current Deferred revenue, current Summary of other operating lease information. Summary Of Other Operating Lease Information Table [Text Block] Summary of Other Operating Lease Information Debt Securities, Available-for-sale, Total Debt Securities, Available-for-Sale Fair Value Net Cash Provided by (Used in) Investing Activities [Abstract] Cash Flows From Investing Activities: Collaboration revenue payment receivable Collaboration Revenue Payment Receivable Collaboration Revenue Payment Receivable Annual increase in number of shares available for issuance as percentage on outstanding shares of common stock on final day of preceding calendar year. Annual Increase In Number Of Shares Available For Issuance As Percentage On Outstanding Shares Of Common Stock On Final Day Of Preceding Calendar Year Annual increases in number of shares available for issuance as percentage of outstanding shares common stock on final day of preceding calendar year Common Stock, Shares, Issued, Total Common Stock, Shares, Issued Common stock shares issued U.S. Treasury notes US Treasury Securities [Member] Minimum [Member] Minimum Stockholders' Equity Attributable to Parent [Abstract] SHAREHOLDERS’ EQUITY Realized and unrealized loss on foreign exchange Foreign Currency Transaction Gain (Loss), before Tax, Total Foreign Currency Transaction Gain (Loss), before Tax Realized and unrealized gain (loss) on foreign exchange Net income Net income (loss) Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Entity Address, Address Line Two Entity Address, Address Line Two Cash and Cash Equivalents [Axis] Cash and Cash Equivalents Revenues [Abstract] Revenue: Lessee, Operating Lease, Lease Not yet Commenced, Description Operating lease, lease not yet commenced, description Award Type [Axis] Award Type Subsequent Event [Member] Subsequent Events Transaction price of the agreement Business Combination, Consideration Transferred Business Combination, Consideration Transferred, Total Other income (expense), net Nonoperating Income (Expense) [Abstract] Research and Development Expense, Total Research and Development Expense Research and development, net of tax credits Entity Central Index Key Entity Central Index Key Lessee, Operating Lease, Existence of Option to Terminate [true false] Lessee, operating lease, existence of option to terminate Research and development services Research and Development Services [Member] Research and Development Services. Accounting Policies [Abstract] Investments, Debt and Equity Securities [Abstract] Debt Securities, Available-for-Sale [Line Items] Schedule Of Available For Sale Securities [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility Measurement Frequency [Axis] Measurement Frequency Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Number of shares granted Share-Based Payment Arrangement [Text Block] Share-Based Compensation General and Administrative Expense, Total General and Administrative Expense General and administrative Organization, Consolidation and Presentation of Financial Statements [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Weighted average exercise price, Outstanding at end of period Weighted average exercise price, Outstanding at beginning of period MOROCCO Cambridge, Massachusetts Research and Development Expense [Member] Research and Development Lease, Cost Total lease costs Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Right-of-use asset obtained in exchange for new operating lease liability Adjustments to reconcile net income (loss) to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Retained Earnings [Member] Accumulated Deficit Money Market Funds [Member] Money Market Funds Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Transaction price of the agreement Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Entity Interactive Data Current Entity Interactive Data Current Other Receivables Other receivables Local Phone Number Local Phone Number Fair Value, Assets Measured on Recurring Basis [Table Text Block] Schedule of Financial Assets Measured at Fair Value on a Recurring Basis Summary of Computation of Basic and Diluted Net Income (Loss) Per Share Attributable To Common Shareholders Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Options to license undruggable target. Options To License Undruggable Target [Member] Options to License Undruggable Targets IPO [Member] Initial Public Offering Lessee, Operating Lease, Existence of Option to Extend [true false] Operating lease, existence of option to extend Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Number of shares, Granted Two thousand twenty employee share purchase plan. Two Thousand Twenty Employee Share Purchase Plan [Member] 2020 Employee Share Purchase Plan Income Statement Location [Domain] Income Statement Location Shares, Outstanding Balance, Shares Balance, Shares Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Entity Incorporation, Date of Incorporation Entity incorporation, date of incorporation Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Number of shares, Outstanding at end of period Number of shares, Outstanding at beginning of period Marketable Securities, Current, Total Marketable Securities, Current Marketable securities Document Fiscal Year Focus Document Fiscal Year Focus Basic Net income (loss) per share attributable to common shareholders--basic Earnings Per Share, Basic, Total Earnings Per Share, Basic Assets [Abstract] ASSETS Marketable securities, Aggregate fair value Investments, Fair Value Disclosure Investments, Fair Value Disclosure, Total Shares Issued, Price Per Share Shares issued, price per share Financial Instrument [Axis] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset Provision for Loan and Lease Losses, Total Provision for Loan and Lease Losses Non-cash lease expense Collaboration revenue receivable Increase Decrease in Collaboration Revenue Receivable Increase decrease in collaboration revenue receivable. Liabilities and Equity [Abstract] LIABILITIES AND SHAREHOLDERS’ EQUITY Antidilutive Securities, Name [Domain] Antidilutive Securities, Name Net income (loss) for the period Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Assets, Current [Abstract] CURRENT ASSETS: Bristol-Myers Squibb Company. Bristol Myers Squibb Company [Member] Bristol-Myers Squibb Company Allowance for credit losses or other impairment charges Debt Securities, Available-for-Sale, Allowance for Credit Loss, Not Previously Recorded Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV Payables and Accruals [Abstract] Measurement Frequency [Domain] Measurement Frequency Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Lease Costs Lease, Cost [Abstract] Entity [Domain] Entity Lessee, Operating Lease, Remaining Lease Term Operating lease, remaining extended lease term Cover [Abstract] Product and Service [Domain] Product and Service Other Nonoperating Expense, Total Other Nonoperating Expense Other expense Liabilities, Current [Abstract] CURRENT LIABILITIES: Maximum [Member] Maximum Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Schedule of Share-based Compensation Expense Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Exercise of stock options, Shares Number of options exercised Number of shares, Exercised Foreign exchange (gain) loss Foreign currency transaction gain (loss). Foreign Currency Transaction Gain Loss Fair Value, Inputs, Level 3 [Member] Significant Other Observable Inputs (Level 3) Use of Estimates, Policy [Policy Text Block] Use of Estimates Stock Issued During Period, Value, Stock Options Exercised Exercise of stock options Clinical trial materials Clinical Trial Materials [Member] Clinical Trial Materials [Member] Trading Symbol Trading Symbol Estimated period of completion of trials to get revenue Estimated Period of Completion of Trials To Get Revenue Estimated period of completion of trials to get revenue. Subsequent Event Type [Axis] Subsequent Event Type Additional clinical development plan Additional Clinical Development Plan [Member] Additional Clinical Development Plan [Member] Smaller reporting company policy text block Smaller Reporting Company Policy Text Block Smaller Reporting Company Other comprehensive loss Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate Accounts Payable, Current, Total Accounts Payable, Current Accounts payable Accrued Property and Equipment Purchases Accrued property and equipment purchases. Accrued property and equipment purchases Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Unrealized losses Unrealized Losses Increase (Decrease) in Other Operating Assets, Total Increase (Decrease) in Other Operating Assets Other non-current assets Other non-current assets Plan Name [Axis] Plan Name Completion of Continuing Trials Completion of Continuing Trials [Member] Completion of Continuing Trials [Member] Common Stock, Shares Authorized, Unlimited [Fixed List] Common stock shares authorized Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset Research activities. Research Activities [Member] Research Activities Variable lease costs Variable Lease, Cost Variable lease costs Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted average exercise price, Granted Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive securities excluded from computation of earnings per share amount